The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Park, Sung Woo | - |
dc.contributor.author | Go, Se-Il | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Bae, Sang-Byung | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kim, Ki Hwan | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Lee, Jung-Hee | - |
dc.contributor.author | Park, Joon Seong | - |
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Park, Keon Woo | - |
dc.contributor.author | Lee, Won-Sik | - |
dc.contributor.author | Lee, Sang Min | - |
dc.contributor.author | Lee, Jeong-Ok | - |
dc.contributor.author | Hyun, Myung Soo | - |
dc.contributor.author | Jo, Deog Yeon | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Cho, Do-Yeun | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Kim, Jeong-A | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Yi, Hyeon Gyu | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Park, Moo-Rim | - |
dc.contributor.author | Shim, Hyeok | - |
dc.contributor.author | Song, Moo-Kon | - |
dc.contributor.author | Kim, Youngdoe | - |
dc.contributor.author | Kim, Kihyun | - |
dc.date.available | 2020-02-27T16:40:59Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 0001-5792 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5335 | - |
dc.description.abstract | Background: The neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic marker in solid and hematological cancers. While the derived NLR (dNLR) was shown to be non-inferior to the NLR in large cohorts of patients with different cancer types, it has not been validated as a prognostic marker for multiple myeloma (MM) to date. Methods: Between May 22, 2011 and May 29, 2014, 176 patients with MM from 38 centers who were ineligible for autologous stem cell transplantation were analyzed. The dNLR was calculated using complete blood count differential data. The optimal dNLR cut-off value according to receiver operating characteristic analysis of overall survival (OS) was 1.51. All patients were treated with melphalan and prednisone combined with bortezomib. Results: The complete response rate was lower in the high dNLR group compared to the low dNLR group (7 vs. 26.1%, respectively; p= 0.0148); the corresponding 2-year OS rates were 72.2 and 84.7%, respectively (p= 0.0354). A high dNLR was an independent poor prognostic factor for OS (hazard ratio 2.217, 95% CI 1.015-4.842; p= 0.0458). Conclusion: The dNLR is a readily available and cheaply obtained parameter in clinical studies, and shows considerable potential as a new prognostic marker for transplantation-ineligible patients with MM. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.relation.isPartOf | ACTA HAEMATOLOGICA | - |
dc.title | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000449075700003 | - |
dc.identifier.doi | 10.1159/000490488 | - |
dc.identifier.bibliographicCitation | ACTA HAEMATOLOGICA, v.140, no.3, pp.146 - 156 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85054127663 | - |
dc.citation.endPage | 156 | - |
dc.citation.startPage | 146 | - |
dc.citation.title | ACTA HAEMATOLOGICA | - |
dc.citation.volume | 140 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Hawk | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Inflammatory markers | - |
dc.subject.keywordAuthor | Lymphocytes | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Neutrophils | - |
dc.subject.keywordAuthor | Prognostic factors | - |
dc.subject.keywordPlus | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject.keywordPlus | NEUTROPHIL/LYMPHOCYTE RATIO | - |
dc.subject.keywordPlus | PRETREATMENT NEUTROPHIL | - |
dc.subject.keywordPlus | PREDICTING SURVIVAL | - |
dc.subject.keywordPlus | SUPPRESSOR-CELLS | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | IMMUNE-SYSTEM | - |
dc.subject.keywordPlus | STAGE-II | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.